"Editas Medicine (NASDAQ:EDIT) is facing mixed sentiment as it approaches its quarterly earnings report, with analysts setting an average price target of $4.70, indicating cautious optimism. However, risks are highlighted by an executive's recent share sale to meet tax obligations, reflecting potential concerns about insider confidence."